Shiga toxin

Meridian Bioscience Announces FDA Clearance for Innovative Curian® Shiga Toxin Assay

Retrieved on: 
Wednesday, April 19, 2023
HUS, STEC, Human, Subjectivity, Workflow, Syndrome, Infection, Campylobacter, Shiga toxin, STX1A, Patient, LIS, FDA, GI, Pharmaceutical industry, Meridian

CINCINNATI, April 19, 2023 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) had granted clearance for the company's new Curian® Shiga Toxin assay.

Key Points: 
  • CINCINNATI, April 19, 2023 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) had granted clearance for the company's new Curian® Shiga Toxin assay.
  • This assay joins Curian HpSA® and Curian Campy as Meridian expands its Curian diagnostic platform to maintain leadership in the gastrointestinal disease testing market.
  • The Curian Shiga Toxin assay is designed for use with the Curian analyzer.
  • The new assay is a rapid, qualitative, fluorescent immunoassay for the simultaneous detection and differentiation of Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) in a single test device.

Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023

Retrieved on: 
Thursday, March 2, 2023
Research, Neurology, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Immune system, GMG, Vaccination, STEC-HUS, Hemolytic–uremic syndrome, Death, Shiga toxin, Acetylcholine receptor, REMS, Syndrome, Neisseria meningitidis, Nausea, Confusion, Attenuated vaccine, Fever, Rash, Risk, Medicine, Meningococcal vaccine, Chelsea Handler, Infection, Vomiting, Disease, Light, Patient safety, Headache, Pharmaceutical industry, Vaccine

ULTOMIRIS is not used in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Key Points: 
  • ULTOMIRIS is not used in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
  • It is not known if ULTOMIRIS is safe and effective in children younger than 1 month of age.
  • It is not known if ULTOMIRIS is safe and effective for the treatment of gMG in children.
  • Your healthcare provider will give you a Patient Safety Card about the risk of meningococcal infection.

Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 for the Prevention of Hemolytic Uremic Syndrome with First-in-class CRISPR-based medicine

Retrieved on: 
Tuesday, October 11, 2022
RPD, Shiga toxin, Disease, Technology, IND, Royal commission, Escherichia coli, Genetically modified bacteria, World Economic Forum, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Synthetic biology, Gene editing, DNA repair, Genetic engineering, Rockefeller University, Platelet, ODD, Acute kidney injury, Dysentery, Food, Anemia, GlaxoSmithKline, Khosla Ventures, Microdeletion syndrome, MIT, STEC, CRISPR, PRV, Bacteria, BLA, DNA, HUS, Death, FDA, Gene, Solution, European Commission, Biologics license application, Pharmaceutical industry, Vaccine, Antibiotics, Shiga Prefecture

Children under 5 years of age are particularly sensitive to the expression of Shiga toxins from E. coli (STEC) bacteria after their ingestion from contaminated foods.

Key Points: 
  • Children under 5 years of age are particularly sensitive to the expression of Shiga toxins from E. coli (STEC) bacteria after their ingestion from contaminated foods.
  • EB003 is IND-enabled with a robust manufacturing process at the 100L-scale, full preclinical package and a clear regulatory path-to-clinic.
  • The FDA grants Orphan Drug Designation to a drug or biologic intended to treat a rare disease or condition, which generally includes a disease or condition that affects fewer than 200,000 individuals in the U.S.
  • The FDA grants Rare Pediatric Disease designation for serious and life-threatening diseases primarily affecting individuals ages 18 or younger and fewer than 200,000 individuals in the United States.

Molecular Templates to Participate in Upcoming Virtual Investor Conferences

Retrieved on: 
Friday, February 26, 2021
Toxins, Shiga toxin

Live webcasts of these presentations will be available in the News and Events section of the MTEM website at www.mtem.com .

Key Points: 
  • Live webcasts of these presentations will be available in the News and Events section of the MTEM website at www.mtem.com .
  • Additionally, replays of the webcasts will be available on the corporate website following the conferences.
  • Molecular Templatesis a clinical-stage company focused on the discovery and development of targeted biologic therapeutics.
  • Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Molecular Templates to Participate in Upcoming Virtual Investor Conferences

Retrieved on: 
Monday, November 16, 2020
Toxins, AB5 toxins, Shiga toxin, Evercore

Live webcasts of the Stifel and Evercore ISI presentations will be available in the News and Events section of the MTEM website at www.mtem.com .

Key Points: 
  • Live webcasts of the Stifel and Evercore ISI presentations will be available in the News and Events section of the MTEM website at www.mtem.com .
  • Additionally, replays of the webcasts will be available on the corporate website following the conferences.
  • Molecular Templatesis a clinical-stage company focused on the discovery and development of targeted biologic therapeutics.
  • Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Molecular Templates to Participate in September Virtual Investor Conferences

Retrieved on: 
Thursday, September 3, 2020
Toxins, AB5 toxins, Shiga toxin

The Cantor Fitzgerald and Morgan Stanley presentations will be webcast live and may be accessed via a link on the Molecular Templates website in the Investors section under Events .

Key Points: 
  • The Cantor Fitzgerald and Morgan Stanley presentations will be webcast live and may be accessed via a link on the Molecular Templates website in the Investors section under Events .
  • Additionally, replays of the webcasts will be available on the corporate website following the conferences.
  • Molecular Templatesis a clinical-stage company focused on the discovery and development of targeted biologic therapeutics.
  • Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Global Escherichia Coli (E. coli) Testing Market Analysis 2020-2025

Retrieved on: 
Tuesday, September 1, 2020
Escherichia coli, Medical specialties, Infectious diseases, Organisms, Escherichia coli O157:H7, Shiga toxin, Escherichia, Escherichia coli O104:H21, Escherichia coli O121

The global Escherichia Coli Testing market is expected to grow with a CAGR of 8.1%, during the forecast period.

Key Points: 
  • The global Escherichia Coli Testing market is expected to grow with a CAGR of 8.1%, during the forecast period.
  • Therefore with the increasing government support and development of drug-resistant species of Escherichia coli (E. coli) are the major driving factor for the global Escherichia coli testing market.
  • North America is expected to hold the largest share globally in the Escherichia coli (E. coli) market in the year 2017.
  • Approximately 40 percent of these infections are caused by the strain Escherichia coli (E. coli) O157:H7, part of the shiga toxin-producing group of Escherichia coli (E. coli) bacteria (STEC) and other 60 percent of Escherichia coli (E. coli) cases are caused by non-0157:H7 shiga toxin-producing Escherichia coli (E. coli) (STEC).

Escherichia Coli (E. coli) Testing Market Outlook Report 2020-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 27, 2020
Health, Pharmaceutical, Escherichia coli, Medical specialties, Infectious diseases, Organisms, Escherichia coli O157:H7, Shiga toxin, Escherichia, Escherichia coli O104:H21, Escherichia coli O121

The global Escherichia Coli Testing market is expected to grow with a CAGR of 8.1%, during the forecast period.

Key Points: 
  • The global Escherichia Coli Testing market is expected to grow with a CAGR of 8.1%, during the forecast period.
  • Therefore with the increasing government support and development of drug-resistant species of Escherichia coli (E. coli) are the major driving factor for the global Escherichia coli testing market.
  • North America is expected to hold the largest share globally in the Escherichia coli (E. coli) market in the year 2017.
  • Approximately 40 percent of these infections are caused by the strain Escherichia coli (E. coli) O157:H7, part of the shiga toxin-producing group of Escherichia coli (E. coli) bacteria (STEC) and other 60 percent of Escherichia coli (E. coli) cases are caused by non-0157:H7 shiga toxin-producing Escherichia coli (E. coli) (STEC).

Ron Simon & Associates Files Jimmy John's E. coli O103 Lawsuit After Jimmy John's Receives FDA Warning Letter

Retrieved on: 
Tuesday, July 21, 2020
Medical specialties, Clinical medicine, Medicine, Bleeding, Hematochezia, Escherichia coli, Shiga toxin, Jimmy John's, E. coli outbreak, Escherichia coli O121, North American E. coli O157:H7 outbreaks

The lawsuit was filed against Jimmy John's on behalf of Erick Johnson, a patron who frequented a local Jimmy John's restaurant in Johnston, Iowa in December of 2019.

Key Points: 
  • The lawsuit was filed against Jimmy John's on behalf of Erick Johnson, a patron who frequented a local Jimmy John's restaurant in Johnston, Iowa in December of 2019.
  • Shortly thereafter, Erick began to experience severe nausea, abdominal cramps, and hematochezia associated with E. coli O103 (Shiga Toxin-Producing E. coli) poisoning.Johnson was hospitalized for three days at Boone County Hospital.
  • After Johnson tested positive for E. coli O103, the Greene County Health Department notified the Iowa Department of Public Health, which determined that he was sickened by the strain associated with the Jimmy John's E. coli outbreak.
  • Mr. Simon and his law firm have established a Jimmy John's E. coli Claim Center to assist victims in the outbreak.The E. coli Claim Center can be reached toll-free at 1-888-335-4901.

27 ill with E. coli O103 in Utah - Second lawsuit filed against Jimmy John's Restaurant

Retrieved on: 
Thursday, April 16, 2020
Marler Clark, Toxins, William Marler, Shiga toxin, Marler, Salt Lake, Escherichia coli

SALT LAKE CITY, April 16, 2020 /PRNewswire/ -- A lawsuit has been filed on behalf of Rebecca Pitt against Jimmy John's Restaurant in the Third Judicial District Court in Salt Lake County.

Key Points: 
  • SALT LAKE CITY, April 16, 2020 /PRNewswire/ -- A lawsuit has been filed on behalf of Rebecca Pitt against Jimmy John's Restaurant in the Third Judicial District Court in Salt Lake County.
  • Ms. Pitt is represented by Marler Clark , The Food Safety Law Firm and Lance Andrew, P.C., a local Salt Lake City firm.
  • Jimmy John's has had a decades-long problem with sickening customers with bacteria-tainted sprouts," said William Marler, managing partner at Marler Clark.
  • After a visit to her primary care physician on February 28, 2020, a stool sample tested positive for Shiga toxin-producing E. coli O103.